comparemela.com

Latest Breaking News On - Reviewing research efforts seeking to raise the bar in myelofibrosis - Page 1 : comparemela.com

Dr Mascarenhas on the Use of Selinexor in Myelofibrosis

John Mascarenhas, MD, discusses the use of selinexor with ruxolitinib in JAK inhibitor–naive myelofibrosis, highlighting the phase 2 XPORT-MF-044 trial

John mascarenhasTisch cancer instituteIcahn school of medicineIcahn schoolMount sinaiBlood cancersMyeloid disordersOnclive tvReviewing research efforts seeking to raise the bar in myelofibrosis

Dr Tantravahi on the Efficacy of Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

Srinivas K. Tantravahi, MBBS, MRCP, discusses the preliminary efficacy of selinexor in combination with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis, as seen in the phase 1 XPORT-MF-034 trial.

United statesSrinivask tantravahiUniversity of utah huntsman cancer instituteUtah huntsman cancer instituteReviewing research efforts seeking to raise the bar in myelofibrosisOnclive tvPhase 1 3 xport mf 034 trialJak inhibitor naive

Dr Gerds on the Importance of Evaluating Selinexor in JAK Inhibitor–Naive Myelofibrosis

Aaron Gerds, MD, discusses the importance of evaluating the efficacy and safety of selinexor in patients with JAK inhibitor–naive myelofibrosis, as assessed in the phase 1/3 XPORT-MF-034 trial.

Aaron gerdsCleveland clinic taussig cancer instituteMedical oncologyReviewing research efforts seeking to raise the bar in myelofibrosisOnclive tvCleveland clinicPhase 1 3 xport mf 034 trial

vimarsana © 2020. All Rights Reserved.